Warner-Lambert Share Selling

4 March 1996

As Warner-Lambert stock hit new records in January, company people, including chief financial officer Ernest Larini, sold company shares valued at $11.9 million. W-L shares have soared about 17%, despite lackluster earnings, ever since Pharmacia & Upjohn announced their merger plans last August.

While the options-related trades came amid speculation that the company is a takeover target, analysts feel the "insider" share sales could be an indication that such a move is not imminent. David Saks of Gruntal & Co questioned why, if the rumors "were so hot and close and employees knew of it," they would be selling. If a takeover were close, an internal auditing commission at the company "would put a muzzle on any insider trading," he added.

A company spokesman said the "insider-share sales" were not unusual, and that company employees periodically exercise their options. All these people exercised options to buy shares at a discount, and sold them at market value. Most of the sales were done on January 2, when the company closed at a record $98.50.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight